INNOVA CAPTAB LIMITED (INNOVACAP) financials

INNOVA CAPTAB LIMITED (INNOVACAP) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Market Cap: ₹5,954Cr.
Current Price: ₹1,040
Stock P/E: 62.4
ROE: 9.85%
ROCE: 10.8%
Book Value: ₹155
Dividend Yield: 0.21%
52W High / Low: ₹1,354/608

In Jun 2026, INNOVA CAPTAB LIMITED (INNOVACAP) reported sales ₹400 Cr and net profit ₹32 Cr.

Annual TTM: sales ₹1,412 Cr, net profit ₹95 Cr.

Shareholding: Promoters 50.90% (Sep 2026), FIIs 0.85% (Sep 2026), DIIs 19.16% (Sep 2026), Public 29.10% (Sep 2026), No. of Shareholders 36,551% (Sep 2026).

INNOVACAP quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	240	249	243	287	290	364	358	400
Expenses	207	216	214	252	260	317	320	346
Operating Profit	33	32	28	35	29	47	39	54
OPM %	14%	13%	12%	12%	10%	13%	11%	14%
Other Income	4	3	4	4	5	3	3	3
Interest	0	0	2	3	5	3	4	4
Depreciation	3	3	8	9	9	9	9	10
Profit before tax	34	33	23	27	19	37	28	43
Tax %	25%	26%	25%	26%	26%	25%	24%	25%
Net Profit	26	24	17	20	14	28	21	32
EPS in Rs	4.48	4.26	2.99	3.55	2.50	4.88	3.70	5.60
Raw PDF	—	—	—	—	—	—	—	—

INNOVACAP profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	373	411	785	859	865	958	1,299	1,412
Expenses	322	356	687	760	755	836	1,147	1,243
Operating Profit	51	54	99	99	110	122	151	169
OPM %	14%	13%	13%	11%	13%	13%	12%	12%
Other Income	1	1	3	9	9	17	13	13
Interest	5	4	5	18	14	2	15	17
Depreciation	10	6	7	11	11	17	37	38
Profit before tax	38	46	89	78	94	120	112	128
Tax %	26%	26%	25%	26%	27%	25%	25%	—
Net Profit	28	34	66	58	68	89	84	95
EPS in Rs	5.81	7.19	13.79	11.99	11.91	15.63	14.62	16.68
Dividend Payout %	0%	0%	0%	0%	0%	0%	14%	—

INNOVACAP balance sheet (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	48	57	57	57
Reserves	98	133	199	220	666	756	829
Borrowings	54	45	176	237	244	329	321
Other Liabilities	81	178	157	173	187	223	339
Total Liabilities	245	368	544	678	1,155	1,365	1,547
Fixed Assets	73	79	161	161	164	637	648
CWIP	0	7	0	22	339	21	15
Investments	0	0	60	60	60	60	101
Other Assets	172	282	322	435	593	647	782
Total Assets	245	368	544	678	1,155	1,365	1,547

INNOVACAP cash flows (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	31	42	58	39	112	20	34
Cash from Investing Activity	-6	-20	-188	-88	-472	-100	-14
Cash from Financing Activity	-23	-19	125	51	368	84	-34
Net Cash Flow	1	3	-5	3	8	4	-14
Free Cash Flow	27	23	-21	-39	-165	-141	-28
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	79%	101%	80%	59%	123%	32%	36%

INNOVACAP shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%	50.90%
FIIs	0.74%	0.35%	0.23%	0.08%	0.10%	0.23%	0.34%	0.85%
DIIs	19.96%	19.77%	19.67%	20.17%	20.24%	20.14%	19.92%	19.16%
Public	28.41%	29.00%	29.20%	28.86%	28.76%	28.74%	28.84%	29.10%
No. of Shareholders	36,692	39,996	41,014	40,245	38,691	36,965	35,881	36,551

INNOVACAP key ratios
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	85	123	81	98	92	95	93
Inventory Days	84	107	63	67	68	94	103
Days Payable	92	132	84	102	111	119	145
Cash Conversion Cycle	77	99	60	63	49	70	51
Working Capital Days	45	39	23	44	58	65	82
ROCE %	—	28%	33%	21%	15%	12%	11%

INNOVACAPUpdated 16 Oct 2026, 11:58

Innova Captab Limited

INNOVACAPUpdated 16 Oct 2026, 11:58

Market Cap

₹5,954Cr.

Current Price

₹1,040

High / Low

₹1,354/608

Stock P/E

62.4

ROE9.85%

ROCE10.8%

Book Value₹155

Face Value₹10.0

Dividend Yield0.21%

About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	219	4	191	1	3	21	29	15	3.19
Sep 2023	212	5	185	2	3	20	29	14	3.01
Dec 2023	236	4	206	2	3	26	27	19	3.26
Mar 2024	198	0	175	6	3	26	25	20	3.45
Jun 2024	227	0	198	5	3	30	25	22	3.9
Sep 2024	240	0	207	4	3	34	25	26	4.48
Dec 2024	249	0	216	3	3	33	26	24	4.26
Mar 2025	243	2	214	4	8	23	25	17	2.99
Jun 2025	287	3	252	4	9	27	26	20	3.55
Sep 2025	290	5	260	5	9	19	26	14	2.5
Dec 2025	364	3	317	3	9	37	25	28	4.88
Mar 2026	358	4	320	3	9	28	24	21	3.7
Jun 2026	400	4	346	3	10	43	25	32	5.6

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2020	373	5	322	1	10	38	26	28	5.81
Mar 2021	411	4	356	1	6	46	26	34	7.19
Mar 2022	785	5	687	3	7	89	25	66	13.79
Mar 2023	859	18	760	9	11	78	26	58	11.99
Mar 2024	865	14	755	9	11	94	27	68	11.91
Mar 2025	958	2	836	17	17	120	25	89	15.63
Mar 2026	1299	15	1147	13	37	112	25	84	14.62
TTM	1412	17	1243	13	38	128	—	95	16.68

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	50.9%
FIIs	0.85%
DIIs	19.16%
Public	29.1%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	50.9%	3.57%	10.31%	35.22%
Mar 2024	50.9%	1.94%	20.78%	26.39%
Jun 2024	50.9%	1.19%	21.24%	26.67%
Sep 2024	50.9%	1.01%	20.61%	27.48%
Dec 2024	50.9%	0.74%	19.96%	28.41%
Mar 2025	50.9%	0.35%	19.77%	29%
Jun 2025	50.9%	0.23%	19.67%	29.2%
Sep 2025	50.9%	0.08%	20.17%	28.86%
Dec 2025	50.9%	0.1%	20.24%	28.76%
Mar 2026	50.9%	0.23%	20.14%	28.74%
Jun 2026	50.9%	0.34%	19.92%	28.84%
Sep 2026	50.9%	0.85%	19.16%	29.1%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2020	12	98	54	81	245	73	0	0	172	245
Mar 2021	12	133	45	178	368	79	7	0	282	368
Mar 2022	12	199	176	157	544	161	0	60	322	544
Mar 2023	48	220	237	173	678	161	22	60	435	678
Mar 2024	57	666	244	187	1155	164	339	60	593	1155
Mar 2025	57	756	329	223	1365	637	21	60	647	1365
Mar 2026	57	829	321	339	1547	648	15	101	782	1547

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2020	31	-6	-23	1
Mar 2021	42	-20	-19	3
Mar 2022	58	-188	125	-5
Mar 2023	39	-88	51	3
Mar 2024	112	-472	368	8
Mar 2025	20	-100	84	4
Mar 2026	34	-14	-34	-14

Key ratios

Historical financial ratios

Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	85	123	81	98	92	95	93
Inventory Days	84	107	63	67	68	94	103
Days Payable	92	132	84	102	111	119	145
Cash Conversion Cycle	77	99	60	63	49	70	51
Working Capital Days	45	39	23	44	58	65	82
ROCE %	—	28%	33%	21%	15%	12%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of INNOVA CAPTAB LIMITED (INNOVACAP)?

The reported market capitalisation for INNOVA CAPTAB LIMITED (INNOVACAP) is ₹5,954Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of INNOVACAP?

The current price shown for INNOVA CAPTAB LIMITED (INNOVACAP) on Fincrux is ₹1,040 with a 52-week high/low of ₹1,354/608.

What is the P/E ratio of INNOVA CAPTAB LIMITED (INNOVACAP)?

The stock P/E for INNOVA CAPTAB LIMITED (INNOVACAP) is 62.4 on Fincrux, with ROE at 9.85% and ROCE at 10.8%.

What were INNOVACAP latest quarterly results?

For Jun 2026, INNOVA CAPTAB LIMITED (INNOVACAP) reported sales ₹400 Cr and net profit ₹32 Cr (figures in ₹ crore unless noted).

What are INNOVACAP annual sales and net profit?

For TTM, INNOVA CAPTAB LIMITED (INNOVACAP) shows sales of ₹1,412 Cr and net profit of ₹95 Cr on the Fincrux profit & loss statement.

Who owns INNOVA CAPTAB LIMITED (INNOVACAP)?

Latest shareholding for INNOVA CAPTAB LIMITED (INNOVACAP) on Fincrux: Promoters 50.90% (Sep 2026), FIIs 0.85% (Sep 2026), DIIs 19.16% (Sep 2026), Public 29.10% (Sep 2026), No. of Shareholders 36,551% (Sep 2026).

Where can I find INNOVA CAPTAB LIMITED (INNOVACAP) financials?

INNOVA CAPTAB LIMITED (INNOVACAP) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show INNOVACAP balance sheet and cash flow?

Yes. The INNOVA CAPTAB LIMITED (INNOVACAP) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 16 October 2026 at 11:58